A Phase II Study of Encorafenib and Binimetinib in People with BRAF V600E-Mutated Non-Small Cell Lung Cancer

Print

Full Title

A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600E-mutant Non-small Cell Lung Cancer

Purpose

The purpose of this study is to evaluate the safety and effectiveness of combining the drugs encorafenib and binimetinib in patients with metastatic non-small cell lung cancer (NSCLC) that contains a BRAF gene mutation called V600E. Encorafenib and binimetinib are used together to treat melanoma; their use in this study is investigational.

BRAF sends signals inside cells that direct cells to grow, but the BRAF mutation can trigger abnormal, uncontrolled tumor growth. Each study drug blocks different proteins involved in tumor growth: encorafenib particularly blocks the mutated BRAF protein and binimetinib targets a protein called MEK. Encorafenib and binimetinib are taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic NSCLC that contains a BRAF V600E mutation.
  • This study is open to newly diagnosed patients as well as those who previously received treatment. However, prior treatment with BRAF or MEK inhibitors is not permitted.
  • At least 2 weeks must pass between the completion of prior treatment and entry into the study.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Michael Offin at 646-449-1778.

Protocol

19-206

Phase

II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators